Kimia Biosciences Fair Value
Kimia Biosciences fair value. Kimia Biosciences (KIMIABL) average fair value is ₹60.03 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹33.2 (+80.81%), fair value range ₹31.0–₹104.58. Check KIMIABL company valuation to track the company's total market size over time.
Fair Value Analysis Export
KIMIABL Fair Value vs Current Price — Valuation Summary
KIMIABL average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore Kimia Biosciences intrinsic price to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
KIMIABL Fair Value Analysis — Data Sources & Coverage
Kimia Biosciences financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit Kimia Biosciences share price chart.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
KIMIABL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Kimia Biosciences P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Divis Laboratories | DIVISLAB | 84.36 | 14.72 | ₹244,125 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Syngene International | SYNGENE | 65.37 | 2.98 | ₹14,538 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.